Valeant Slips After JPMorgan Says Sell On Stretched Valuation, High Expectations
December 14, 2017 at 16:16 PM EST
Shares of Valeant Pharmaceuticals are sliding after JPMorgan analyst Chris Schott downgraded the stock to Underweight.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|